CD19 and hematopoietic and lymphoid cell neoplasm: This tactic has been most successfully used in hematological cancers, especially B-cell malignancies where CD19 is the intended target although, as noted earlier, myeloma cell CD19 per se has not been demonstrated to be particularly amenable as an immunotherapeutic target.